ArticleTargeted oncology2024

Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.

Yoshinori Kagawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.